Neratinib, sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer. The most common side effect is diarrhea, which affects nearly all patients. It is an orally administered, small molecule irreversible inhibitor of HER family kinases with primary activity against HER2, EGFR and HER4 achieved through covalent binding to a conserved cysteine in the ATP binding site. Recommended clinical use in the adjuvant setting is 240 mg once daily for up to 12 months following completion of trastuzumab based therapy, with concurrent antidiarrheal prophylaxis advised. Neratinib is metabolized predominantly via CYP3A4, has important drug interactions with strong CYP3A inhibitors and inducers, and requires dose modification in patients with hepatic impairment. Analytical characterization uses LC-MS and HPLC methods for potency, impurity profiling and stability testing, and formulation development focuses on improving oral tolerability and consistent exposure when taken with food.
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Parent: Neratinib
Typical quality specifications for neratinib drug substance and finished product include tight limits on related substances and degradation products to ensure safety and stability. Industry specifications commonly limit individual specified related compounds to the range of 0.1 to 0.3 percent w/w and total impurities to not more than about 1.0 percent w/w, with unidentified impurities above 0.05 to 0.10 percent w/w triggering investigation and identification. Process related residuals such as solvents and catalysts are controlled to ICH thresholds, and heavy metals and genotoxic impurities are monitored to meet applicable guidance. Routine impurity profiling uses validated HPLC and LC-MS methods, forced degradation studies to define degradation pathways, and established acceptance criteria for each identified impurity in the regulatory dossier.
Neratinib is used as extended adjuvant therapy in adults with early-stage HER2 positive breast cancer following completion of trastuzumab based therapy, and it may also be used in certain metastatic HER2 positive settings according to clinical judgment and guideline recommendations.
Neratinib irreversibly inhibits HER family receptor tyrosine kinases by covalently binding to a cysteine residue in the ATP binding pocket, blocking receptor autophosphorylation and downstream signaling pathways that drive tumor cell proliferation and survival.
Clinical trials have shown that neratinib provides a statistically significant improvement in invasive disease free survival when used as extended adjuvant therapy in appropriate HER2 positive populations, with the magnitude of benefit varying by patient subgroup and hormone receptor status. Absolute and relative benefit depend on prior treatments and individual risk factors, so efficacy should be discussed with an oncologist for a personalized estimate.
Cost varies by country, pharmacy, insurance coverage and available patient assistance programs. In many markets out of pocket monthly costs can range from several thousand to over ten thousand dollars without coverage. Patients should consult their healthcare provider, pharmacist or manufacturer assistance services for current pricing and support options.
